NCT03085797View on ClinicalTrials.gov

Effect of Mepolizumab in Severe Bilateral Nasal Polyps

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Nasal Polyps
Interventions
DRUG

Mepolizumab

Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.

DRUG

Placebo

Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.

DRUG

Mometasone furoate

All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).

Trial Locations (101)

1602

GSK Investigational Site, Florida

1900

GSK Investigational Site, La Plata

2010

GSK Investigational Site, Darlinghurst

2145

GSK Investigational Site, Westmead

3004

GSK Investigational Site, Melbourne

3169

GSK Investigational Site, Clayton

4000

GSK Investigational Site, San Miguel de Tucumán

5500

GSK Investigational Site, Mendoza

6150

GSK Investigational Site, Murdoch

7600

GSK Investigational Site, Mar del Plata

10016

GSK Investigational Site, New York

13353

GSK Investigational Site, Berlin

15213

GSK Investigational Site, Pittsburgh

18017

GSK Investigational Site, Bethlehem

21162

GSK Investigational Site, White Marsh

21565

GSK Investigational Site, Incheon

23235

GSK Investigational Site, Richmond

23507

GSK Investigational Site, Norfolk

23538

GSK Investigational Site, Lübeck

24501

GSK Investigational Site, Lynchburg

27103

GSK Investigational Site, Winston-Salem

27607

GSK Investigational Site, Raleigh

28105

GSK Investigational Site, Matthews

29118

GSK Investigational Site, Orangeburg

29425

GSK Investigational Site, Charleston

32746

GSK Investigational Site, Lake Mary

35209

GSK Investigational Site, Birmingham

40205

GSK Investigational Site, Louisville

40225

GSK Investigational Site, Düsseldorf

48149

GSK Investigational Site, Münster

50265

GSK Investigational Site, West Des Moines

50312

GSK Investigational Site, Des Moines

60657

GSK Investigational Site, Chicago

63141

GSK Investigational Site, St Louis

65183

GSK Investigational Site, Wiesbaden

65201

GSK Investigational Site, Columbia

70072

GSK Investigational Site, Marrero

72076

GSK Investigational Site, Tübingen

73120

GSK Investigational Site, Oklahoma City

75070

GSK Investigational Site, McKinney

75235

GSK Investigational Site, Dallas

78258

GSK Investigational Site, San Antonio

80907

GSK Investigational Site, Colorado Springs

81377

GSK Investigational Site, Munich

81675

GSK Investigational Site, Munich

83706

GSK Investigational Site, Boise

84102

GSK Investigational Site, Salt Lake City

84341

GSK Investigational Site, North Logan

92103

GSK Investigational Site, San Diego

92506

GSK Investigational Site, Riverside

95661

GSK Investigational Site, Roseville

97504

GSK Investigational Site, Medford

119991

GSK Investigational Site, Moscow

123095

GSK Investigational Site, Moscow

123182

GSK Investigational Site, Moscow

127473

GSK Investigational Site, Moscow

142190

GSK Investigational Site, Moscow

150003

GSK Investigational Site, Yaroslavl

190013

GSK Investigational Site, Saint Petersburg

194356

GSK Investigational Site, Saint Petersburg

197022

GSK Investigational Site, Saint-Peterburgh

400015

GSK Investigational Site, Cluj-Napoca

500091

GSK Investigational Site, Brasov

500283

GSK Investigational Site, Brasov

540098

GSK Investigational Site, Târgu Mureş

08854

GSK Investigational Site, Piscataway

C1414AIF

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

S2000DBS

GSK Investigational Site, Rosario

C1121ABE

GSK Investigational Site, Buenos Aires

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

V5Z 1M9

GSK Investigational Site, Vancouver

L8L 2X2

GSK Investigational Site, Hamilton

N6A 4V2

GSK Investigational Site, London

K1G 6C6

GSK Investigational Site, Ottawa

H2X 1P1

GSK Investigational Site, Montreal

H3G 1L5

GSK Investigational Site, Montreal

S7K 1N4

GSK Investigational Site, Saskatoon

G1S 4L8

GSK Investigational Site, Québec

01139

GSK Investigational Site, Dresden

01307

GSK Investigational Site, Dresden

1105 AZ

GSK Investigational Site, Amsterdam

014452

GSK Investigational Site, Bucharest

463-707

GSK Investigational Site, Seongnam-si Gyeonggi-do

03722

GSK Investigational Site, Seoul

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

SE-413 45

GSK Investigational Site, Gothenburg

SE-251 87

GSK Investigational Site, Helsingborg

SE-221 85

GSK Investigational Site, Lund

SE-114 86

GSK Investigational Site, Stockholm

SE-171 76

GSK Investigational Site, Stockholm

DL3 6HX

GSK Investigational Site, Darlington

L9 7AL

GSK Investigational Site, Liverpool

SE1 9RT

GSK Investigational Site, London

SW3 6HP

GSK Investigational Site, London

WC1X 8DA

GSK Investigational Site, London

M23 9QZ

GSK Investigational Site, Manchester

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne

S60 2UD

GSK Investigational Site, Rotherham

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

CRF Health

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT03085797 - Effect of Mepolizumab in Severe Bilateral Nasal Polyps | Biotech Hunter | Biotech Hunter